Literature DB >> 11546724

Thiopentone and methohexital, but not pentobarbitone, reduce early focal cerebral ischemic injury in rats.

D J Cole1, L M Cross, J C Drummond, P M Patel, W K Jacobsen.   

Abstract

PURPOSE: Although barbiturates are considered to be cerebral protectants, little is known regarding the relative efficacy of different barbiturates to reduce ischemic brain injury. In a model of middle cerebral artery occlusion (MCAo), we compared the relative effects of 1.0 and 0.4 burst-suppression doses of thiopentone, methohexital, and pentobarbitone on cerebral infarct.
METHODS: During isoflurane anesthesia, MCAo was achieved via a temporal craniotomy. Thirty minutes before MCAo the rats were randomized to receive one of the following which was maintained throughout the study. Halothane (n=20)-1.2 MAC halothane, thiopentone (n=20), methohexital (n=20), or pentobarbitone (n=20). The first ten animals in each barbiturate group received the respective barbiturate in a dose sufficient to maintain burst-suppression of the electroencephalogram (3-5 bursts x min(-1)). The subsequent ten animals in each barbiturate group received 40% of the burst-suppression dose. After 180 min of MCAo and 120 min of reperfusion, cerebral injury was assessed.
RESULTS: For the burst-suppression animals, injury volume (mm3, mean +/- SD) was less in the thiopentone group (88 +/- 14) than the halothane (133 +/- 17), methohexital (126 +/- 19), or pentobarbitone (130 +/- 17) groups (P <0.05). For 0.4 burst-suppression animals, injury volume was less for the methohexital group (70 +/- 22) than the halothane (124 +/- 24), thiopentone (118 +/- 15), or pentobarbitone (121 +/- 20) groups (P <0.05).
CONCLUSIONS: These data are inconsistent with the longstanding assumption that electrophysiologically comparable doses of the various classes of barbiturates have equivalent protective efficacy. They in turn suggest that mechanisms other than, or at least in addition to, metabolic suppression may contribute to the protective effect of barbiturates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11546724     DOI: 10.1007/BF03016699

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  4 in total

Review 1.  Management of traumatic brain injury: some current evidence and applications.

Authors:  A Guha
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

2.  Propofol increases expression of basic fibroblast growth factor after transient cerebral ischemia in rats.

Authors:  Xiao-Chun Zhao; Li-Min Zhang; Dong-Yi Tong; Ping An; Chao Jiang; Ping Zhao; Wei-Min Chen; Jian Wang
Journal:  Neurochem Res       Date:  2012-12-18       Impact factor: 3.996

3.  Pentobarbital versus thiopental in the treatment of refractory intracranial hypertension in patients with traumatic brain injury: a randomized controlled trial.

Authors:  Jon Pérez-Bárcena; Juan A Llompart-Pou; Javier Homar; Josep M Abadal; Joan M Raurich; Guillem Frontera; Marta Brell; Javier Ibáñez; Jordi Ibáñez
Journal:  Crit Care       Date:  2008-08-29       Impact factor: 9.097

4.  Thiopental inhibits global protein synthesis by repression of eukaryotic elongation factor 2 and protects from hypoxic neuronal cell death.

Authors:  Christian I Schwer; Cornelius Lehane; Timo Guelzow; Simone Zenker; Karl M Strosing; Sashko Spassov; Anika Erxleben; Bernd Heimrich; Hartmut Buerkle; Matjaz Humar
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.